{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:44Z","timestamp":1791828584695,"version":"4.3.4"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on axSpA evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare demographic and disease-specific parameters of axPsA and axSpA+pso.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RABBIT-SpA is a prospective longitudinal cohort study. AxPsA was defined based on (1) clinical judgement by rheumatologists; (2) imaging (sacroiliitis according to modified New York criteria in radiographs or signs of active inflammation in MRI or syndesmophytes\/ankylosis in radiographs or signs of active inflammation in spine MRI). axSpA was stratified into axSpA+pso\u2009and axSpA without pso.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Psoriasis was documented in 181\/1428 axSpA patients (13%). Of 1395 PsA patients, 359 (26%) showed axial involvement. 297 patients (21%) fulfilled the clinical definition and 196 (14%) the imaging definition of axial manifestation of PsA. AxSpA+pso differed from axPsA regardless whether clinical or imaging definition was used. axPsA patients were older, more often female and less often HLA-B27+. Peripheral manifestations were more often present in axPsA than in axSpA+pso, whereas uveitis and inflammatory bowel disease were more common in axSpA+pso. Burden of disease (patient global, pain, physician global) was similar among axPsA and axSpA+pso patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AxPsA differs from axSpA+pso in its clinical manifestations, irrespective of whether axPsA is defined clinically or by imaging. These findings support the hypothesis that axSpA and PsA with axial involvement are distinct entities, so extrapolation of treatment data from randomised controlled trials in axSpA should be performed with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002837","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:01:13Z","timestamp":1678435273000},"page":"e002837","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04434885","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne Constanze","family":"Regierer","sequence":"first","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2190","authenticated-orcid":false,"given":"Anja","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-033X","authenticated-orcid":false,"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectiology and Rheumatology (Including Nutrition Medicine), Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine & Pharmacology ITMP, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center, Berlin, Germany"},{"name":"Department of Gastroenterology, Infectiology and Rheumatology (Including Nutrition Medicine), Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V Hematology Oncology Rheumatology, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Worsch","sequence":"additional","affiliation":[{"name":"Rheumatologist, Muehlhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center, Berlin, Germany"},{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2025090312165340000_9.1.e002837.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2025090312165340000_9.1.e002837.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025090312165340000_9.1.e002837.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"2025090312165340000_9.1.e002837.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312165340000_9.1.e002837.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209853"},{"key":"2025090312165340000_9.1.e002837.6","first-page":"30","article-title":"Updates on axial psoriatic arthritis from the 2020 grappa annual meeting","volume":"97","author":"Gladman","year":"2021","journal-title":"J Rheumatol"},{"key":"2025090312165340000_9.1.e002837.7","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of spondyloarthritis international society (ASAS) and the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312165340000_9.1.e002837.8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312165340000_9.1.e002837.9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312165340000_9.1.e002837.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.3.135"},{"key":"2025090312165340000_9.1.e002837.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2025090312165340000_9.1.e002837.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-022-00861-w","article-title":"Author correction: group for research and assessment of psoriasis and psoriatic arthritis (grappa): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312165340000_9.1.e002837.13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00393-019-0613-z","article-title":"[RABBIT-spa: a new disease register for axial spondyloarthritis and psoriatic arthritis]","volume":"79","author":"Regierer","year":"2020","journal-title":"Z Rheumatol"},{"key":"2025090312165340000_9.1.e002837.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132845","article-title":"Axial psoriatic disease: clinical and imaging assessment of an underdiagnosed condition","volume":"10","author":"Giovannini","year":"2021","journal-title":"J Clin Med"},{"key":"2025090312165340000_9.1.e002837.15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2021.03.007","article-title":"Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort","volume":"51","author":"Feld","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312165340000_9.1.e002837.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2707"},{"key":"2025090312165340000_9.1.e002837.17","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatology"},{"key":"2025090312165340000_9.1.e002837.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in tnfi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"key":"2025090312165340000_9.1.e002837.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2025090312165340000_9.1.e002837.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221422"},{"key":"2025090312165340000_9.1.e002837.21","doi-asserted-by":"crossref","unstructured":"Gladman DD , Mease PJ , Bird P , et al . Correspondence on \u201cNo efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019?\u201d by Braun and Landew\u00e9. Ann Rheum Dis 2022. doi:10.1136\/annrheumdis-2022-222161 [Epub ahead of print 29 Apr 2022].","DOI":"10.1136\/annrheumdis-2022-222161"},{"key":"2025090312165340000_9.1.e002837.22","doi-asserted-by":"crossref","unstructured":"Landew\u00e9 RB , Braun J . Response to: correspondence on \u201cNo efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019?\u201d by Braun and Landew\u00e9. Ann Rheum Dis 2022. doi:10.1136\/annrheumdis-2022-222359 [Epub ahead of print 29 Apr 2022].","DOI":"10.1136\/annrheumdis-2022-222359"},{"key":"2025090312165340000_9.1.e002837.23","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/annrheumdis-2018-213334","article-title":"Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis","volume":"77","author":"Yap","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312165340000_9.1.e002837.24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/acr.24174","article-title":"The phenotype of axial spondyloarthritis: is it dependent on HLA-B27 status?","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312165340000_9.1.e002837.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222562"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:16:59Z","timestamp":1756927019000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/rmdopen-2022-002837"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002837","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}